8-K: Silexion Therapeutics Shareholders Approve Reverse Stock Split, Equity Plan Expansion, and Director Elections at Reconvened Annual Meeting

Silexion Therapeutics Corp. shareholders approved a 1-for-15 reverse stock split, an increase in the equity incentive plan, and the election of seven directors at its reconvened 2025 annual general meeting after an initial quorum failure.

Summary

• Silexion Therapeutics Corp. reconvened its 2025 annual general meeting on July 14, 2025, after the initial meeting on July 7, 2025, was adjourned due to a lack of quorum.
• At the reconvened meeting, 1,054,899 ordinary shares, representing approximately 12.1% of outstanding shares, were present.
• A quorum was established in accordance with Article 21.3 of the company's amended and restated articles of association, allowing the shareholders present to conduct business despite not meeting the initial majority requirement.
• Shareholders approved the election of seven directors: Ilan Hadar (96.9% in favor), Dror J. Abramov (96.9% in favor), Ruth Alon (68.2% in favor), Ilan Levin (68.1% in favor), Avner Lushi (96.8% in favor), Shlomo Noy (97% in favor), and Amnon Peled (97% in favor).
• The appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent public accountants for the year ending December 31, 2025, was ratified with 98.3% of votes in favor.
• A proposal to effect a 1-for-15 reverse share split was approved with 59.6% of votes in favor, which will consolidate ordinary shares and change the par value from $0.0009 to $0.0135 per share.
• An increase of 1,271,859 ordinary shares (to a total of 1,428,268 shares, adjusted for the reverse split) reserved for issuance under the company's 2024 Equity Incentive Plan was approved with 58.3% of votes in favor.

Sentiment

Score: 6

Explanation: The successful approval of all proposals, including a reverse stock split and an expanded equity incentive plan, provides management with tools for strategic maneuvers and employee incentives. However, the initial quorum failure and significant shareholder opposition to key proposals (reverse split and equity plan) indicate underlying challenges in shareholder engagement and consensus, tempering overall positive sentiment.

Positives

• All proposed resolutions, including the election of directors, ratification of auditors, reverse share split, and increase in the equity incentive plan, were successfully approved by shareholders.
• The company was able to proceed with its annual general meeting agenda despite initial quorum challenges, demonstrating flexibility in its corporate governance framework (Article 21.3).
• The high approval rates for most director nominees (over 96%) and the auditor ratification (98.3%) indicate strong shareholder confidence in these specific areas.

Negatives

• The initial annual general meeting on July 7, 2025, was adjourned due to the absence of a quorum, indicating a potential lack of shareholder engagement or difficulty in reaching the required participation threshold.
• The reconvened meeting proceeded with a significantly lower quorum (approximately 12.1% of outstanding shares) than initially required, which might raise questions about broad shareholder representation in the decisions made.
• The proposals for the reverse share split (59.6% in favor) and the increase in the equity incentive plan (58.3% in favor) faced substantial opposition, with over 40% of votes against each, suggesting significant shareholder dissent on these key strategic matters.
• Two director nominees, Ruth Alon and Ilan Levin, received notably lower approval rates (68.2% and 68.1% respectively) compared to other nominees, indicating less widespread support for their re-election.

Risks

• The significant opposition (over 40%) to the reverse share split and the increase in the equity incentive plan indicates potential shareholder dissatisfaction or concern regarding these strategic decisions, which could lead to future governance challenges or investor relations issues.
• A reverse share split, while potentially aimed at increasing share price and maintaining listing compliance, can sometimes be perceived negatively by the market and may not guarantee a sustained increase in share price.
• Increasing the equity incentive plan could lead to potential dilution for existing shareholders if a large number of new shares are issued under the plan.

Future Outlook

The approval of the 1-for-15 reverse share split indicates a strategic move to consolidate shares, potentially to increase the per-share price and meet listing requirements or improve market perception. The significant increase in shares reserved for the equity incentive plan suggests a future intent to use equity for compensation or other corporate purposes, which will be proportionally adjusted following the reverse split.

Management Comments

• Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Industry Context

Reverse stock splits are often undertaken by companies whose stock price has fallen significantly, sometimes below exchange minimums, to increase the per-share price and maintain listing compliance. Increasing equity incentive plans is a common practice for companies to attract and retain talent, aligning employee interests with shareholder value, though the size of the increase relative to outstanding shares can be a point of investor scrutiny.

Comparison to Industry Standards

• The approval of a reverse stock split is a common strategy for companies facing low stock prices, often to meet minimum bid price requirements of exchanges like Nasdaq. For example, many small-cap biotech or technology companies have implemented similar splits to avoid delisting.
• The significant opposition (over 40%) to both the reverse split and the equity plan increase is higher than typical for routine corporate actions, suggesting a notable segment of shareholders holds reservations about these specific strategic directions, which could be a point of concern compared to companies with more unified shareholder bases.
• The ability to establish a quorum with a minority of shares (12.1%) after an initial failure, as per Article 21.3, is a specific governance mechanism that allows the company to proceed with business, but it is less common for major decisions to be made with such a low percentage of shareholder participation in more mature or larger companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the approval of the reverse share split, which will reduce the number of shares they hold while increasing the par value per share. Also impacted by the increase in the equity incentive plan, which could lead to future dilution. The election of directors determines the company's leadership.
• Employees: Potentially benefit from the expanded equity incentive plan, which provides more shares for compensation and incentives, aligning their interests with company performance.
• Management/Board of Directors: Gained shareholder approval for key strategic initiatives (reverse split, equity plan increase) and confirmation of their positions, providing a mandate to proceed with their plans.

Next Steps

• Implementation of the 1-for-15 reverse share split, which will consolidate issued and outstanding ordinary shares and adjust the par value.
• Adjustment of the number of ordinary shares reserved under the 2024 Equity Incentive Plan proportionally based on the reverse share split.
• Kesselman & Kesselman will audit the company's accounts for the year ending December 31, 2025, and the additional period until the next annual general meeting.
• The newly elected directors will serve on the Board of Directors until the next annual general meeting and until their successors are elected and qualified.

Key Dates

Recommendation

Keywords

Silexion Therapeutics, SLXN, 8-K filing, annual general meeting, shareholder vote, reverse stock split, equity incentive plan, director election, corporate governance, auditor ratification, Nasdaq